Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Todays approval in the frontline consolidation phase, regardless of MRD status, allows us to reach more patients than ever with this transformative, first-in-class Bispecific T-cell Engager (BiTE) therapy, Jay Bradner, executive vice president of research and development and chief scientific officer at Amgen, said in a press release
Label every reconstituted vial with the date, concentration, and diluent used
(2018) The Multifaceted role of glutathione S-transferases in cancer, Cancer Lett
Andreeff M , Jacamo R, Hoang NM, Zeng Z, Piya S, Burks J, Al-Rawi A, Borthakur G, Battula L, Zhang W, Han L, Mak PY, Mu H, Nguyen K, Ruvolo V, Wang X, Baran N, Mak D, Ruvolo P, Bueso-Ramos C, Benton CB, Konoplev S, Kornblau S, Carter B, Zal T, Konopleva M
PAHSAs attenuate immune responses and promote beta cell survival in autoimmune diabetic mice
